Association of advanced age with concentrations of uraemic toxins in CKD

Journal of Nephrology

Volumn 29, Issue 1, 2016, Pages 81-91

  Rroji, Merita ^a   Eloot, Sunny ^b   Dhondt, Annemie ^b   Van Biesen, Wim ^b   Glorieux, Griet ^b   Neirynck, Nathalie ^b   Vandennoortgate, Nele ^b   Liabeuf, Sophie ^c,d   Massy, Ziad ^c,e   Vanholder, Raymond ^b  

^a UNIVERSITY HOSPITAL CENTER MOTHER TERESA   (Albania)

^b GHENT UNIVERSITY HOSPITAL   (Belgium)

^c UNIVERSITÉ DE PICARDIE JULES VERNE   (France)

^d AMIENS UNIVERSITY HOSPITAL   (France)

^e LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

CKD; Elderly; Haemodialysis; Renal function; Uraemic

Indexed keywords

6 N,N' DIMETHYLARGININE; BETA 2 MICROGLOBULIN; CARBOXYMETHYL FURANPROPIONIC ACID; CRESYLSULFATE; CYSTATIN C; GLUCURONIDE; HIPPURIC ACID; INDICAN; INDOLEACETIC ACID; N(G),N(G) DIMETHYLARGININE; PROPIONIC ACID; UNCLASSIFIED DRUG; UREMIC TOXIN; URIC ACID; 3-CARBOXY-4-METHYL-5-PROPYL-2-FURANPROPANOIC ACID; ARGININE; BIOLOGICAL MARKER; CREATININE; FURAN DERIVATIVE; N,N-DIMETHYLARGININE; PROPIONIC ACID DERIVATIVE;

ACYLATION; ADULT; AGE; AGED; AGING; ARTICLE; BLOOD ANALYSIS; BLOOD LEVEL; BODY MASS; CHRONIC KIDNEY DISEASE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLUORESCENCE; GLOMERULUS FILTRATION RATE; HEMODIALYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NEPHELOMETRY; PROTEIN DEGRADATION; PROTEIN INTAKE; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; UREA NITROGEN BLOOD LEVEL; ANALOGS AND DERIVATIVES; BLOOD; COMPARATIVE STUDY; MIDDLE AGED; MULTIVARIATE ANALYSIS; RENAL INSUFFICIENCY, CHRONIC; UREMIA; VERY ELDERLY;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; ARGININE; BETA 2-MICROGLOBULIN; BIOMARKERS; BLOOD UREA NITROGEN; CREATININE; FEMALE; FURANS; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROPIONATES; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; UREMIA;

EID: 84961319822     PISSN: 11218428     EISSN: 17246059     Source Type: Journal    
DOI: 10.1007/s40620-015-0195-z     Document Type: Article

References (59)

1. Boult C, Altmann M, Gilbertson D, Yu C, Kane RL (1996) Decreasing disability in the 21st century: the future effects of controlling six fatal and nonfatal conditions. Am J Public Health 86:1388–1393
2. van Oostrom SH, Picavet HS, de Bruin Sr et al (2014) Multimorbidity of chronic diseases and health care utilization in general practice. BMC Fam Pract 15:61
3. Wetzels JF, Kiemeney LA, Swinkels DW, Willems HL, den Heijer M (2007) Age- and gender-specific reference values of estimated GFR in Caucasians: the Nijmegen Biomedical Study. Kidney Int 72:632–637
4. Hemmelgarn BR, Zhang J, Manns BJ et al (2006) Progression of kidney dysfunction in the community-dwelling elderly. Kidney Int 69:2155–2161
5. Glassock RJ, Winearls C (2008) Screening for CKD with eGFR: doubts and dangers. Clin J Am Soc Nephrol 3:1563–1568
6. Anderson S, Halter JB, Hazzard WR et al (2009) Prediction, progression, and outcomes of chronic kidney disease in older adults. J Am Soc Nephrol 20:1199–1209
7. Canaud B, Tong L, Tentori F et al (2011) Clinical practices and outcomes in elderly hemodialysis patients: results from the Dialysis Outcomes and Practice Patterns Study (DOPPS). Clin J Am Soc Nephrol 6:1651–1662
8. Vanholder R, Schepers E, Pletinck A, Nagler EV, Glorieux G (2014) The uremic toxicity of indoxyl sulfate and p-cresyl sulfate: a systematic review. J Am Soc Nephrol 25(9):1897–1907
9. Meyer TW, Hostetter TH (2007) Uremia. N Engl J Med 357:1316–1325
10. Vanholder R, Massy Z, Argiles A, Spasovski G, Verbeke F, Lameire N (2005) Chronic kidney disease as cause of cardiovascular morbidity and mortality. Nephrol Dial Transplant 20:1048–1056
11. Cheung AK, Rocco MV, Yan G et al (2006) Serum beta-2 microglobulin levels predict mortality in dialysis patients: results of the HEMO study. J Am Soc Nephrol 17:546–555
12. Liabeuf S, Lenglet A, Desjardins L et al (2012) Plasma beta-2 microglobulin is associated with cardiovascular disease in uremic patients. Kidney Int 82:1297–1303
13. Liabeuf S, Barreto DV, Barreto FC et al (2010) Free p-cresylsulphate is a predictor of mortality in patients at different stages of chronic kidney disease. Nephrol Dial Transplant 25:1183–1191
14. Barreto FC, Barreto DV, Liabeuf S et al (2009) Serum indoxyl sulfate is associated with vascular disease and mortality in chronic kidney disease patients. Clin J Am Soc Nephrol 4:1551–1558
15. Meijers BK, Claes K, Bammens B et al (2010) p-Cresol and cardiovascular risk in mild-to-moderate kidney disease. Clin J Am Soc Nephrol 5:1182–1189
16. Kielstein JT, Zoccali C (2005) Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 46:186–202
17. Meijers BK, Evenepoel P (2011) The gut-kidney axis: indoxyl sulfate, p-cresyl sulfate and CKD progression. Nephrol Dial Transplant 26:759–761
18. Schepers E, Glorieux G, Vanholder R (2010) The gut: the forgotten organ in uremia? Blood Purif 29:130–136
19. Schmucker DL (1998) Aging and the liver: an update. J Gerontol A Biol Sci Med Sci 53:B315–B320
20. Kinirons MT, O’Mahony MS (2004) Drug metabolism and ageing. Br J Clin Pharmacol 57:540–544
21. Hopkins MJ, Sharp R, Macfarlane GT (2001) Age and disease related changes in intestinal bacterial populations assessed by cell culture, 16S rRNA abundance, and community cellular fatty acid profiles. Gut 48:198–205
22. Sydow K, Fortmann SP, Fair JM et al (2010) Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin Chem 56:111–120
23. Kielstein JT, Bode-Boger SM, Frolich JC, Ritz E, Haller H, Fliser D (2003) Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation 107:1891–1895
24. Schulze F, Maas R, Freese R, Schwedhelm E, Silberhorn E, Boger RH (2005) Determination of a reference value for N(G), N(G)-dimethyl-l-arginine in 500 subjects. Eur J Clin Invest 35:622–626
25. Matrai Z, Nemeth J, Miklos K, Szabo Z, Masszi T (2009) Serum beta2-microglobulin measured by immunonephelometry: expression patterns and reference intervals in healthy adults. Clin Chem Lab Med 47:585–589
26. Kuzuya M, Ando F, Iguchi A, Shimokata H (2002) Effect of aging on serum uric acid levels: longitudinal changes in a large Japanese population group. J Gerontol A Biol Sci Med Sci 57:M660–M664
27. Marquez IO, Tambra S, Luo FY et al (2011) Contribution of residual function to removal of protein-bound solutes in hemodialysis. Clin J Am Soc Nephrol 6:290–296
28. Eloot S, Schepers E, Barreto DV et al (2011) Estimated glomerular filtration rate is a poor predictor of concentration for a broad range of uremic toxins. Clin J Am Soc Nephrol 6:1266–1273
29. Neirynck N, Eloot S, Glorieux G et al (2012) Estimated glomerular filtration rate is a poor predictor of the concentration of middle molecular weight uremic solutes in chronic kidney disease. PLoS ONE 7:e44201
30. Cockcroft DW, Gault MH (1976) Prediction of creatinine clearance from serum creatinine. Nephron 16:31–41
31. Fagugli RM, De Smet R, Buoncristiani U, Lameire N, Vanholder R (2002) Behavior of non-protein-bound and protein-bound uremic solutes during daily hemodialysis. Am J Kidney Dis 40:339–347
32. Daugirdas JT (1993) Second generation logarithmic estimates of single-pool variable volume Kt/V: an analysis of error. J Am Soc Nephrol 4:1205–1213
33. Jindal KK, Goldstein MB (1988) Urea kientic modeling in chronic hemodialysis: benefits, problems, and practical solutions. Semin Dial 1:82–85
34. Eloot S, Van Biesen W, Glorieux G, Neirynck N, Dhondt A, Vanholder R (2013) Does the adequacy parameter Kt/V(urea) reflect uremic toxin concentrations in hemodialysis patients? PLoS One 8:e76838
35. Stevens LA, Coresh J, Schmid CH et al (2008) Estimating GFR using serum cystatin C alone and in combination with serum creatinine: a pooled analysis of 3,418 individuals with CKD. Am J Kidney Dis 51:395–406
36. Deneva-Koycheva TI, Vladimirova-Kitova LG, Angelova EA, Tsvetkova TZ (2011) Plasma asymmetric dimethylarginine levels in healthy people. Folia Med (Plovdiv) 53:28–33
37. Isobe C, Abe T, Terayama Y (2010) Decrease in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in cerebrospinal fluid during elderly aging and in patients with sporadic form of amyotrophic lateral sclerosis. Neurosignals 18:43–48
38. Schnabel R, Blankenberg S, Lubos E et al (2005) Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 97:e53–e59
39. Stanga Z, Nock S, Medina-Escobar P, Nydegger UE, Risch M, Risch L (2013) Factors other than the glomerular filtration rate that determine the serum beta-2-microglobulin level. PLoS One 8:e72073
40. Viaene L, Thijs L, Jin Y et al (2014) Heritability and clinical determinants of serum indoxyl sulfate and p-cresyl sulfate, candidate biomarkers of the human microbiome enterotype. PLoS ONE 9:e79682
41. Davies SJ, Davenport A (2014) The role of bioimpedance and biomarkers in helping to aid clinical decision-making of volume assessments in dialysis patients. Kidney Int 86:489–496
42. Kyle UG, Genton L, Hans D, Karsegard L, Slosman DO, Pichard C (2001) Age-related differences in fat-free mass, skeletal muscle, body cell mass and fat mass between 18 and 94 years. Eur J Clin Nutr 55:663–672
43. Dittmar M, Reber H, Hofmann G (2001) Age-related decline in body cell mass in elderly men and women, determined by a noninvasive nuclear technique: effects of physical activity and dietary potassium intake. Am J Hum Biol 13:204–211
44. Nicholls A, Scott JT (1972) Effect of weight-loss on plasma and urinary levels of uric acid. Lancet 2:1223–1224
45. Garg JP, Chasan-Taber S, Blair A et al (2005) Effects of sevelamer and calcium-based phosphate binders on uric acid concentrations in patients undergoing hemodialysis: a randomized clinical trial. Arthritis Rheum 52:290–295
46. Cupisti A, Saba A, D’Alessandro C et al (2009) Dimethylarginine levels and nutritional status in hemodialysis patients. J Nephrol 22:623–629
47. Glass RL, Krick TP, Sand DM, Rahn CH, Schlenk H (1975) Furanoid fatty acids from fish lipids. Lipids 10:695–702
48. Hannemann K, Puchta V, Simon E, Ziegler H, Ziegler G, Spiteller G (1989) The common occurrence of furan fatty acids in plants. Lipids 24:296–298
49. Mabuchi H, Nakahashi H (1988) A major inhibitor of phenytoin binding to serum protein in uremia. Nephron 48:310–314
50. Mabuchi H, Nakahashi H (1988) Inhibition of hepatic glutathione S-transferases by a major endogenous ligand substance present in uremic serum. Nephron 49:281–283
51. Sun H, Frassetto L, Benet LZ (2006) Effects of renal failure on drug transport and metabolism. Pharmacol Ther 109:1–11
52. Sun H, Huang Y, Frassetto L, Benet LZ (2004) Effects of uremic toxins on hepatic uptake and metabolism of erythromycin. Drug Metab Dispos 32:1239–1246
53. Itoh Y, Ezawa A, Kikuchi K, Tsuruta Y, Niwa T (2012) Protein-bound uremic toxins in hemodialysis patients measured by liquid chromatography/tandem mass spectrometry and their effects on endothelial ROS production. Anal Bioanal Chem 403:1841–1850
54. Sassa T, Matsuno H, Niwa M et al (2000) Measurement of furancarboxylic acid, a candidate for uremic toxin, in human serum, hair, and sweat, and analysis of pharmacological actions in vitro. Arch Toxicol 73:649–654
55. Muller MJ, Geisler C, Pourhassan M, Gluer CC, Bosy-Westphal A. Assessment and definition of lean body mass deficiency in the elderly. Eur J Clin Nutr (in press)
56. Garcia-Garcia FJ, Carcaillon L, Fernandez-Tresguerres J et al (2014) A new operational definition of frailty: the frailty trait scale. J Am Med Dir Assoc 15:371
57. Kelaiditi E, Cesari M, Canevelli M et al (2013) Cognitive frailty: rational and definition from an (I.A.N.A./I.A.G.G.) international consensus group. J Nutr Health Aging 17:726–734
58. Johansen KL, Dalrymple LS, Delgado C et al (2014) Association between body composition and frailty among prevalent hemodialysis patients: a US Renal Data System special study. J Am Soc Nephrol 25:381–389
59. Hallan SI, Matsushita K, Sang Y et al (2012) Age and association of kidney measures with mortality and end-stage renal disease. JAMA 308:2349–2360